Patent classifications
A61L2300/45
PHARMACEUTICAL COMPOSITIONS AND DEVICE METHODS FOR TREATMENT OF PROLIFERATIVE DISEASES
A method for treating proliferative diseases by delivering a combination of at least two pharmaceutically active agents to a diseased area or tissue comprising a coating layer of two hydrophobic drugs applied to an exterior surface of a device or a substrate wherein the first pharmaceutically active agent is selected from a group consisting of mTor inhibitors and the second pharmaceutically active agent is selected from a group of consisting of NF-kβ inhibitors. Further a method for treating proliferative diseases by delivering a combination of at least two pharmaceutically active agents to a diseased area or tissue comprising: a coating layer of two hydrophobic drugs applied to an exterior surface of a medical device or substrate and a polymer blend carrier for the pharmaceutically active agents.
Resorbable pouches for implantable medical devices
Biodegradable and resorbable polymer pouches are described for use with cardiac rhythm management devices (CRMs) and other implantable medical devices (IMDs), i.e., a pouch, covering, or other receptacle capable of encasing, surrounding and/or holding the CRM or other IMD for the purpose of securing it in position, inhibiting or reducing bacterial growth, providing pain relief and/or inhibiting scarring or fibrosis on or around the CRM or other IMD. Optionally, the biodegradable and resorbable pouches of the invention include one or more drugs in the polymer matrix to provide prophylactic effects and alleviate side effects or complications associated with the surgery or implantation of the CRM or other IMD.
MEDICAL DEVICES AND METHODS OF MAKING MEDICAL DEVICES
A medical device material impregnated with a combination of antimicrobial agents, the combination of antimicrobial agents comprising a first antimicrobial agent, the first antimicrobial agent being triclosan and at least a second antimicrobial agent, wherein the combination of antimicrobial agents provides the device material with antimicrobial activity and inhibition of resistant microbial mutations for of the order of, or greater than, 80 days.
EXTRACELLULAR MATRIX SHEET STRUCTURES
An implantable medical product and method of use for substantially reducing or eliminating harsh biological responses associated with conventionally implanted medical devices, including inflammation, infection and thrombogenesis, when implanted in in a body of a warm blooded mammal. The bioremodelable pouch structure is configured and sized to receive, encase and retain an electrical medical device therein and to allow such device to be inserted into the internal region or cavity of the pouch structure; with the pouch structure formed from either: (a) first and second sheets, or (b) a single sheet having first and second sheet portions. After receiving the electrical device, the edges around the opening are closed by suturing or stapling. The medical device encased by the bioremodelable pouch structure effectively improves biological functions by promoting tissue regeneration, modulated healing of adjacent tissue or growth of new tissue when implanted in the body of the mammal.
Coating and coating method
The present invention discloses a coating for a medical implant, wherein at least a part of said coating contains an osseointegration agent and the same and/or a different part of the coating contains an antimicrobial metal agent.
Tissue thickness compensator comprising at least one medicament
A stapling assembly comprising a tissue thickness compensator is disclosed. The tissue thickness compensator comprises a body portion comprising a porous material and a plurality of cavities defined in the body portion, wherein the cavities are aligned with forming surfaces of an anvil such that fasteners of a fastener cartridge are configured to at least one of the cavities when the fasteners are ejected from the fastener cartridge or capture the cavities and compress the cavities within the tissue thickness compensator when the fasteners are ejected from the fastener cartridge and formed by forming surfaces of the anvil. The stapling assembly further comprises at least one medicament positioned within each cavity prior to firing the stapler, wherein the medicament is different than the porous material.
Layer of material for a surgical end effector
A staple cartridge comprising a tissue thickness compensator is disclosed. The tissue thickness compensator comprises an uncompressed height, a compressed height, an outer encasement, and tubular structures aligned along the longitudinal axis. The tubular structures are configured to collapse when pressure is applied to the tissue thickness compensator by tissue during the firing motion.
Antimicrobial compositions of aminoglycosidic antibiotics and zinc ion chelators specifically formulated for enhanced inhibition of bacterial colonization and antibacterial efficacy
Pharmaceutical compositions comprising an aminoglycosidic antibiotic and at least one zinc-chelating agent in a specified concentration, and methods of inhibiting bacterial colonization, biofilm formation and if treating bacterial infections utilizing the compositions are provided. Topical formulations suitable for wound care, and surface-applicable formulations suitable for medical, industrial and household disinfecting needs are also described.
Compositions for Regenerating Defective or Absent Myocardium
Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
PHARMACEUTICAL PREPARATION AND METHOD OF ITS PRODUCTION AND USE
Thus, the present invention provides a composition in powder form comprising highly dispersed silica particles, polymethylsiloxane particles, and a cationic surfactant, wherein at least 25% by weight of the cationic surfactant is present in primary polymethylsiloxane particles carrying the cationic surfactant on their surface and/or in agglomerates of these primary particles.